United States: New York Federal Court Allows Truthful And Non-Misleading Off-Label Promotion

The U.S. District Court for the Southern District of New York recently granted Amarin Pharma, Inc. preliminary relief against the U.S. Food and Drug Administration's attempted restriction of certain truthful and non-misleading communications about off-label use of its approved drug, Vescepa.1 Significantly, this decision reinforces limits to the FDA's ability to restrict off-label promotion since the Second Circuit's 2012 ruling in U.S. v. Caronia2.


The FDA approved Vescepa for the treatment of severe hypertriglyceridemia ("very high triglycerides") in July 2012, but it rejected a subsequent proposed use to treat high triglyceride levels in patients who were already on statin therapy ("persistently high triglycerides"). Even though the agency had concluded that the drug was safe and effective at reducing triglyceride levels, it believed that clinical study data had raised a "substantial scientific issue" as to whether this reduction in the second patient population would reduce their overall cardiovascular risk. With that denial, the FDA cautioned that marketing Vascepa for this second proposed use would expose Amarin to criminal liability for misbranding under the Federal Drug & Cosmetic Act (FDCA) and to civil liability under the False Claims Act.

Because they perceived this FDA "threat" to restrict Amarin's truthful and non-misleading statements about studies of Vascepa's use to treat persistently high triglycerides, Amarin and several doctors filed suit against the FDA in May 2015 in the Southern District of New York. The complaint seeks recognition that FDA's prohibition of off-label promotion—as applied to these statements—violates the First Amendment. It also seeks a ruling to allow Amarin to engage with doctors in these communications without risk of criminal prosecution, even if the communications constitute off-label promotion.

On May 22, 2015, Amarin moved for a preliminary injunction to prevent the FDA from filing a misbranding suit for its proposed communications with doctors about Vascepa. Notably, this dispute required Judge Engelmayer to address the parties' disagreement about the scope of Caronia. In that 2012 decision, the Second Circuit had held that the First Amendment applied to a pharmaceutical representative's communications regarding off-label use and protected the company and its representative from misbranding charges because he had made only truthful and non-misleading statements. In view of Caronia, Amarin reasoned that its statements at-issue were therefore protected from Government prosecution. In response, the FDA attempted to moot this dispute by setting forth specific conditions and statements to which it would not bring a misbranding action. The FDA further argued that the Second Circuit had intended to limit Caronia to its facts, and the agency therefore could continue to bring misbranding actions against off-label promotion even when it consisted of only truthful and non-misleading statements.

On August 7, 2015, Judge Engelmayer granted Amarin's requested preliminary relief and found that the FDA's limited acceptance of these statements did not moot the controversy. Not only had Amarin rejected the FDA's conditions under which it would not take action, but the agency's limited acceptance of Amarin's proposed communications had highlighted the statements to which the FDA had reserved its right to bring a misbranding action.

With regard to the breadth of Caronia's holding, Judge Engelmayer rejected the FDA's position. Referencing Caronia, Judge Engelmayer reasoned that the Supreme Court decisions in Central Hudson3 and Sorrell v. IMS Health, Inc.4—holding that the First Amendment provides qualified protection to commercial speech and that pharmaceutical marketing constitutes such speech—place limits upon interpretation of the FDCA's misbranding provisions. Thus, Caronia properly had applied the Central Hudson analysis to truthful and non-misleading statements about off-label use to hold that the FDA could not bring a misbranding action when the act at-issue consists exclusively of these statements. Judge Engelmayer also emphasized that the speaker's intent was not relevant to Caronia's holding, noting that the Second Circuit had examined "the very types of statements . . . that the FDA most disfavors."

Potential Impacts and Limits of the Amarin Decision

It remains unclear whether the FDA will appeal this decision to the Second Circuit, the same court that authored Caronia. Nonetheless, this development places significant pressure on the FDA to revise its historically stringent enforcement approach against off-label promotion. Even after Caronia, the FDA has maintained its position that it will police and prosecute truthful and non-misleading statements related to off-label use of approved drugs. For example, the FDA issued draft guidance in February 2014, stating it would allow pharmaceutical manufacturers to distribute scientific and medical journal articles that discuss off-label uses for approved drugs, so long as the articles include certain disclosures. The draft guidance warned, however, that the agency would continue to use as evidence of misbranding any statements by representatives that characterize these articles to support the safety or effectiveness of the off-label use. Moreover, the FDA agreed in June 2014 to comprehensively review its regulations on communications concerning off-label promotion, but it has yet to provide any updates. Judge Engelmayer's decision underscores the need for FDA to resolve the growing tension between its longstanding policies and recent case law.

While Amarin provides some assurance to pharmaceutical companies seeking to make truthful and non-misleading statements about off-label use, it highlights Caronia's distinction between those statements and conduct related to off-label promotion. Whereas the Government cannot prosecute truthful and non-misleading statements alone as misbranding after Caronia, Judge Engelmayer noted that the Second Circuit preserved the Government's ability to use these communications as evidence of intent to misbrand in cases involving additional actionable conduct, such as kickbacks.

This decision also emphasizes the impact of scientific and medical developments to potential corporate liability for communications related to off-label promotion. In granting the motion, Judge Engelmayer carefully limited Amarin's relief to the specific communications at-issue. Whereas Amarin's proposed statements are factually accurate and not misleading based upon the current FDA-approved study data and commentary, Judge Engelmayer cautioned that Amarin bears responsibility to monitor for scientific and medical developments that may impact the statements' truthful or non-misleading nature. Likewise, pharmaceutical companies seeking to make presently truthful and non-misleading statements related to off-label use must be vigilant of new evidence that may alter the statements' character and give rise to liability for misbranding. Moreover, these companies should take significant measures to assure that representatives are likewise informed of scientific developments and adjust their marketing materials and statements accordingly.


1. Amarin Pharma, Inc. v. U.S. Food & Drug Administration, Case No. 1:15-cv-03588 (S.D.N.Y.).

2. 703 F.3d 149 (2d Cir. 2012).

3. Central Hudson Gas & Elec. Co. v. Public Serv. Comm'n of New York, 447 U.S. 557 (1980).

4. Sorrell v. IMS Health Inc., 131 S. Ct. 2653 (2011).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.